Press Releases
DTx Pharma announces acquisition by Novartis
Breaking open new therapeutic areas for RNA medicines
DTx Pharma is solving one of the biggest challenges limiting the development of genetic medicines: the delivery of RNA therapeutics beyond the liver.
Platform
Overcoming obstacles in RNA therapeutics
Enabled by our world-class expertise in short interfering RNAs (siRNA) design and in leveraging fatty acid pharmacology to enable drug delivery, we have developed the groundbreaking FALCON (Fatty Acid Ligand Conjugated OligoNucleotides) platform. By linking naturally occurring fatty acids onto siRNAs, FALCON overcomes two key hurdles facing the siRNA delivery field: cellular uptake and biodistribution beyond the liver.
Pipeline
Expanding the reach of genetic medicines to patients who need them most
Our pipeline of novel therapeutic candidates is expanding the target tissues and patient populations that can be served by RNA therapeutics, beginning with rare, previously untreatable peripheral nervous system, muscle, and CNS disorders.
About Us
World-class leadership to solve long-standing limitations
Our highly accomplished team has deep knowledge on both fatty acid pharmacology and siRNA design, as well as decades of drug development experience, enabling us to execute on our mission to treat diseases previously inaccessible to RNA therapeutics.
Join Us
Reveal the potential of genetic medicines with us
At DTx Pharma, we are a group of driven, rigorous and innovative thinkers who are determined to transform patient lives by innovating impactful genetic medicines for patients in need.
